Evidence mapPaperPMID 39736697Full record

ArticleAlzheimer's research & therapy2024

Sex differences in the relationships between 24-h rest-activity patterns and plasma markers of Alzheimer's disease pathology.

Maxime Van Egroo, Elise Beckers, Nicholas J Ashton, Kaj Blennow, Henrik Zetterberg, Heidi I L Jacobs

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maxime Van EgrooFaculty of Health, Medicine and Life Sciences, Mental Health and Neuroscience Research Institute, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands. m.vanegroo@maastrichtuniversity.nl.
Elise BeckersFaculty of Health, Medicine and Life Sciences, Mental Health and Neuroscience Research Institute, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Heidi I L JacobsFaculty of Health, Medicine and Life Sciences, Mental Health and Neuroscience Research Institute, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands.

Funding

Research Education ComponentP30AG072980 · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · 2025 to 2025
$3.1M
The wandering nerve: gateway to boost Alzheimer's disease related cognitive performanceR01AG068062 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$808k
Locus coeruleus network architecture of Alzheimer's disease vulnerabilityR01AG082006 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$671k
AD Strategic Fund and the Alzheimer's Association #ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-CAlzheimer Nederland #WE.03-2019-02Alzheimer's Association AARG-22-920434Alzheimer's Association 2021 Zenith Award ZEN-21-848495Alzheimer's Drug Discovery Foundation #201809-2016862Alzheimer's Drug Discovery Foundation #RDAPB-201809-2016615BrightFocus Foundation A20211016FEuropean Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant 860197 (MIRIADE)European Union's Horizon Europe research and innovation programme 101053962European Union's Marie Skłodowska-Curie Actions 101109451-ADEEPSLEEPHjärnfonden #FO2017-0243 and #ALZ2022-0006Hjärnfonden #FO2022-0270NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG062559NIA NIH HHS R01 AG068062NIA NIH HHS R01 AG068398NIA NIH HHS R01 AG082006NIA NIH HHS R21 AG074220NIH HHS #1R01AG068398-01NIH HHS R01AG062559, R01AG06806, R01AG082006, and R21AG074220Swedish Alzheimer Foundation #AF-930351, #AF-939721 and #AF-968270Swedish Research Council #2017-00915Swedish Research Council #2023-00356; #2022-01018 and #2019-02397Swedish State Support for Clinical Research #ALFGBG-71320Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement #ALFGBG-715986 and #ALFGBG-965240UK Dementia Research Institute at UCL UKDRI-1003
6 · The paper itself

Abstract

backgroundAlthough separate lines of research indicated a moderating role of sex in both sleep-wake disruption and in the interindividual vulnerability to Alzheimer's disease (AD)-related processes, the quantification of sex differences in the interplay between sleep-wake dysregulation and AD pathology remains critically overlooked. Here, we examined sex-specific associations between circadian rest-activity patterns and AD-related pathophysiological processes across the adult lifespan.

methodsNinety-two cognitively unimpaired adults (mean age = 59.85 ± 13.77 years, range = 30-85, 47 females) underwent 10 days of actigraphic recordings, and blood drawing. Standard non-parametric indices of 24-h rest-activity rhythm fragmentation (intradaily variability, IV) and stability (interdaily stability, IS) were extracted from actigraphy data using the GGIR package. Plasma concentrations of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), amyloid-β

resultsHigher IV, indicating worse 24-h rest-activity rhythm fragmentation, was associated with elevated levels of plasma NfL (t(85) = 4.26, P < 0.0001), GFAP (t(85) = 2.49, P = 0.01), and at trend level with lower Aβ

conclusionsThese findings suggest that the association between disrupted circadian rest-activity patterns and AD pathophysiological processes may be more evident in cognitively unimpaired males. Our results contribute to the precision medicine approach, and they have clinical implications for improved early detection and selection of at-risk individuals to be enrolled in preventive interventions.

Indexed as

ActigraphyAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersRestSex Characteristicstau ProteinsAdultAgedAged, 80 and overCircadian RhythmFemaleGlial Fibrillary Acidic ProteinHumansMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinMAPT protein, humanneurofilament protein LNeurofilament ProteinsPeptide Fragmentstau Proteins24-h rest-activity patternsActigraphyAmyloid-betaGlial fibrillary acidic proteinInterdaily stabilityIntradaily variabilityNeurofilament light chainPlasma biomarkersSex differencesTau

Identifiers

PMID39736697
PMCPMC11684129

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.